AstraZeneca PLC (AZN.L)
Chart Events
Performance Outlook
| Previous Close | 10,380.00 |
| Open | 10,464.00 |
| Bid | 10,760.00 x 0 |
| Ask | 10,762.00 x 0 |
| Day's Range | 10,422.00 - 10,792.00 |
| 52 Week Range | 8,029.00 - 11,000.00 |
| Volume | |
| Avg. Volume | 2,718,620 |
| Market Cap | 166.963B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 134.20 |
| EPS (TTM) | 80.30 |
| Earnings Date | Apr 28, 2022 - May 02, 2022 |
| Forward Dividend & Yield | 2.10 (2.04%) |
| Ex-Dividend Date | Feb 24, 2022 |
| 1y Target Est | 110.79 |
- Investor's Business Daily
Dow Jones Surges 650 Points, Led By Salesforce Stock; Johnson & Johnson, Astrazeneca Form Bullish Patterns
The Dow Jones was up sharply in afternoon trading, along with the Nasdaq and S&P 500. Airbnb was a top gainer in the Nasdaq 100.
- Zacks
Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).
- Benzinga
AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder
AstraZeneca Plc (NASDAQ: AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised. The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of care (SoC) arm, including in patients who had been treated previously for an average of 10 years. In the trial, people taking AL
